Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions ...

A recent study found that men with low testosterone levels were associated with a 60 percent higher risk that prostate cancer could progress to a more aggressive state over time. Prostate cancer is ...

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.